By Nigel Walker, Managing Director, That’s Nice
More than ever, pharmaceutical and biotechnology companies are considering CROs and CMOs as partners in collaboration to achieve long-term development goals.
The Nice Insight 2015 industry survey of emerging pharma buyer groups showed how these companies today are choosing and evaluating strategic partners and the provider qualities that are most important to them. For the purposes of the survey, a strategic partnership is defined as a long-term commitment between two organizations to achieve specific business objectives by maximizing the effectiveness of each participant’s resources. The survey indicates that nearly three-quarters (73 percent) of the emerging pharma companies surveyed are interested or very interested in becoming involved in a strategic partnership with a CRO or CMO in the next 12 to 18 months.